KR20200110377A - 조합 용량의 독성을 최소화하기 위한 프로토콜 및 검증을 위한 조영제 - Google Patents

조합 용량의 독성을 최소화하기 위한 프로토콜 및 검증을 위한 조영제 Download PDF

Info

Publication number
KR20200110377A
KR20200110377A KR1020207023337A KR20207023337A KR20200110377A KR 20200110377 A KR20200110377 A KR 20200110377A KR 1020207023337 A KR1020207023337 A KR 1020207023337A KR 20207023337 A KR20207023337 A KR 20207023337A KR 20200110377 A KR20200110377 A KR 20200110377A
Authority
KR
South Korea
Prior art keywords
agent
conjugate
tumor
subject
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207023337A
Other languages
English (en)
Korean (ko)
Inventor
브라이언 헤른
다니엘 브이. 산티
숀 폰테인
개리 더블유 애슐리
Original Assignee
프로린크스 엘엘시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로린크스 엘엘시 filed Critical 프로린크스 엘엘시
Publication of KR20200110377A publication Critical patent/KR20200110377A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyethers (AREA)
KR1020207023337A 2018-01-12 2019-01-11 조합 용량의 독성을 최소화하기 위한 프로토콜 및 검증을 위한 조영제 Ceased KR20200110377A (ko)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201862617095P 2018-01-12 2018-01-12
US62/617,095 2018-01-12
US201862674483P 2018-05-21 2018-05-21
US62/674,483 2018-05-21
US201862700147P 2018-07-18 2018-07-18
US62/700,147 2018-07-18
US201862711423P 2018-07-27 2018-07-27
US201862711421P 2018-07-27 2018-07-27
US62/711,421 2018-07-27
US62/711,423 2018-07-27
US201862716796P 2018-08-09 2018-08-09
US201862716788P 2018-08-09 2018-08-09
US62/716,796 2018-08-09
US62/716,788 2018-08-09
PCT/US2019/013306 WO2019140266A1 (en) 2018-01-12 2019-01-11 Protocol for minimizing toxicity of combination dosages and imaging agent for verification

Publications (1)

Publication Number Publication Date
KR20200110377A true KR20200110377A (ko) 2020-09-23

Family

ID=67218383

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207023337A Ceased KR20200110377A (ko) 2018-01-12 2019-01-11 조합 용량의 독성을 최소화하기 위한 프로토콜 및 검증을 위한 조영제
KR1020207023338A Ceased KR20200109345A (ko) 2018-01-12 2019-01-11 상승적 암 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207023338A Ceased KR20200109345A (ko) 2018-01-12 2019-01-11 상승적 암 치료

Country Status (10)

Country Link
US (4) US11730836B2 (cg-RX-API-DMAC7.html)
EP (2) EP3737383A4 (cg-RX-API-DMAC7.html)
JP (3) JP2021510702A (cg-RX-API-DMAC7.html)
KR (2) KR20200110377A (cg-RX-API-DMAC7.html)
CN (2) CN111587115A (cg-RX-API-DMAC7.html)
AU (2) AU2019206623A1 (cg-RX-API-DMAC7.html)
CA (2) CA3087628A1 (cg-RX-API-DMAC7.html)
MX (3) MX2020007442A (cg-RX-API-DMAC7.html)
RU (1) RU2020126774A (cg-RX-API-DMAC7.html)
WO (2) WO2019140271A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020219943A1 (en) 2019-04-26 2020-10-29 Prolynx Llc Slow-release cytokine conjugates
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
US12472261B2 (en) 2019-08-28 2025-11-18 Prolynx Llc Conjugated inhibitors of DNA damage response
CN119213060A (zh) * 2022-04-14 2024-12-27 国立研究开发法人量子科学技术研究开发机构 单一高分子颗粒、活性分子复合物、单一高分子颗粒的制造方法、肿瘤尺寸的计测方法、肿瘤内微细结构的计测方法、生物体组织的成像方法、药物递送体系、造影剂试剂盒
US20260034120A1 (en) * 2022-08-04 2026-02-05 Prolynx Llc Treating cancer with long-acting topoisomerase i inhibitor
WO2024030998A2 (en) * 2022-08-04 2024-02-08 Prolynx Llc Methods of treating cancer with long-acting topoisomerase i inhibitor

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2319854B1 (en) 1997-01-08 2016-11-30 Sigma-Aldrich Co. LLC Bioconjugation Of Macromolecules
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
AU2003253890A1 (en) 2002-07-12 2004-02-02 Biomarin Pharmaceutical Inc. The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
CA2502870C (en) 2002-10-31 2011-07-26 Nippon Kayaku Kabushiki Kaisha High-molecular weight derivatives of camptothecins
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
CN1852740B (zh) 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
MX2009002855A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales.
EP2307032A4 (en) * 2008-05-22 2014-08-20 Univ Ramot NEW CONJUGATES OF POLYMERS WITH A THERAPEUTIC AGENT AND AN ANGIOGENESIS TARGETING PART CONTAINED THEREOF, AND USES IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS
CN102076331B (zh) 2008-06-26 2013-12-18 普罗林科斯有限责任公司 具有可控的药物释放速率的前药和药物-大分子轭合物
US20100098654A1 (en) 2008-10-21 2010-04-22 Fabio Pastorino Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
EP2366105A1 (en) 2008-11-18 2011-09-21 Baxter International Inc. Methods of determining polydispersity and/or molecular weight distribution of a polyethylene glycol sample
JP2012528240A (ja) 2009-05-28 2012-11-12 メルサナ セラピューティックス, インコーポレイテッド 可変速度放出リンカーを含むポリアル−薬物コンジュゲート
CA2780645C (en) * 2009-11-18 2018-01-16 Nektar Therapeutics Salt form of a multi-arm polymer-drug conjugate
WO2011140393A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled release from macromolecular conjugates
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
WO2011140376A1 (en) 2010-05-05 2011-11-10 Prolynx Llc Controlled drug release from dendrimers
TW201215412A (en) 2010-08-30 2012-04-16 Sun Pharma Advanced Res Co Ltd Stable pharmaceutical composition
CN108721284A (zh) * 2010-11-16 2018-11-02 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合
WO2012088282A1 (en) 2010-12-21 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
IN2014MN01819A (cg-RX-API-DMAC7.html) 2012-03-05 2015-07-03 Univ Ramot
TWI486341B (zh) * 2012-05-18 2015-06-01 高雄醫學大學 抑制atr與fancd2激活之組成物與方法
WO2014194289A1 (en) * 2013-05-31 2014-12-04 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents
CN106061483B (zh) * 2013-10-04 2021-01-08 普洛林克斯有限责任公司 Sn-38的缓释结合物
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015118338A1 (en) * 2014-02-07 2015-08-13 Mission Therapeutics Limited Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways
US20150343100A1 (en) * 2014-05-28 2015-12-03 Memorial Sloan Kettering Cancer Center Bimodal fluorophore-labeled liposomes and associated methods and systems
EP3180031A1 (en) * 2014-08-13 2017-06-21 The Johns Hopkins University Selective dendrimer delivery to brain tumors
WO2016028636A1 (en) 2014-08-16 2016-02-25 Memorial Sloan Kettering Cancer Center Helical polycarbodiimide polymers and associated imaging, diagnostic, and therapeutic methods
JP6378584B2 (ja) 2014-08-29 2018-08-22 キヤノン株式会社 通信システム、画像処理装置、画像処理装置の制御方法、及びプログラム
US10196412B2 (en) * 2014-12-24 2019-02-05 The Board Of Trustees Of The Leland Stanford Junior University Probe for imaging PARP-1 activity
PL3277681T3 (pl) 2015-04-02 2019-10-31 Merck Patent Gmbh Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm
HK1250646A1 (zh) * 2015-04-07 2019-01-11 Memorial Sloan Kettering Cancer Center 纳米粒子免疫偶联物
US10973925B2 (en) * 2015-04-28 2021-04-13 University Of Central Florida Research Foundation Inc. Methods and compositions for theranostic nanoparticles
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
US10821195B2 (en) 2015-09-10 2020-11-03 Memorial Sloan Kettering Cancer Center Compositions for therapeutics, targeted PET imaging and methods of their use
US12048753B2 (en) 2015-10-01 2024-07-30 Whitehead Institute For Biomedical Research Labeling of antibodies
US11154538B2 (en) 2016-02-29 2021-10-26 Synta Pharmaceuticals Corporation Combination therapy for treatment of ovarian cancer
WO2017172678A1 (en) * 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
RU2725292C2 (ru) 2016-04-27 2020-06-30 Иммьюномедикс, Инк. Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
AU2017258415B2 (en) * 2016-04-29 2023-03-30 Cornell University Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors
CN106084005B (zh) * 2016-06-15 2020-02-14 广州军区广州总医院 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用
CN107050471A (zh) * 2016-12-27 2017-08-18 中国药科大学 基于富勒烯的靶向且具有快速清除特征的显像纳米探针及其制备方法和应用

Also Published As

Publication number Publication date
AU2019208024A1 (en) 2020-08-13
MX2020007306A (es) 2020-09-25
KR20200109345A (ko) 2020-09-22
EP3737416A1 (en) 2020-11-18
CN111587126A (zh) 2020-08-25
JP2021510701A (ja) 2021-04-30
US20240082436A1 (en) 2024-03-14
CA3087628A1 (en) 2019-07-18
WO2019140266A1 (en) 2019-07-18
MX2020007442A (es) 2020-09-14
US20230321286A1 (en) 2023-10-12
RU2020126774A (ru) 2022-02-14
JP2024012442A (ja) 2024-01-30
JP7703001B2 (ja) 2025-07-04
WO2019140271A2 (en) 2019-07-18
RU2020126853A3 (cg-RX-API-DMAC7.html) 2022-02-14
JP2021510702A (ja) 2021-04-30
EP3737383A4 (en) 2021-12-15
EP3737383A2 (en) 2020-11-18
US20200360545A1 (en) 2020-11-19
WO2019140271A3 (en) 2019-08-22
MX2023005786A (es) 2023-05-29
US20200397778A1 (en) 2020-12-24
US11730836B2 (en) 2023-08-22
RU2020126853A (ru) 2022-02-14
AU2019206623A1 (en) 2020-07-16
CA3087967A1 (en) 2019-07-18
EP3737416A4 (en) 2022-03-30
CN111587115A (zh) 2020-08-25

Similar Documents

Publication Publication Date Title
US20230321286A1 (en) Protocol for minimizing toxicity of combination dosages and imaging agent for verification
Kotagiri et al. Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer
Hendrikse et al. Visualization of multidrug resistance in vivo
KR102087854B1 (ko) 단백질-중합체-약물 접합체
JP2023504286A (ja) 薬物送達のためのデンドリマー組成物および方法
CA3017954A1 (en) Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors
JP7793205B2 (ja) 癌の免疫療法のための高性能ペプチド及び可変ナノ粒子
TWI904072B (zh) 治療癌症之方法
JP2024178159A (ja) 癌を治療する方法
Sharma et al. EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment
Sachindra et al. SPECT/CT imaging, biodistribution and radiation dosimetry of a 177Lu-DOTA-integrin αvβ6 cystine knot peptide in a pancreatic cancer xenograft model
US20250312498A1 (en) Protocol for minimizing toxicity of combination dosages and imaging agent for verification
Del Vecchio et al. Scintigraphic detection of multidrug resistance in cancer
WO2013106824A1 (en) Epherin receptor targeting agents
US20210388361A1 (en) Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same
Kong et al. Multifunctional Probe Based on “Chemical Antibody–Aptamer” for Noninvasive Detection of PD-L1 Expression in Cancer
Liu et al. Exploring the impact of PEGylation on pharmacokinetics: a size-dependent effect of polyethylene glycol on prostate-specific membrane antigen inhibitors
Hendrikse Monitoring interactions at ATP-dependent drug efflux pumps.
WO2015183876A1 (en) Bimodal fluorophore-labeled liposomes and associated methods and systems
Bellat et al. A urinary drug-disposing approach as an alternative to intravesical chemotherapy for treating nonmuscle invasive bladder cancer
CN116157159A (zh) 使用结构域外-b纤连蛋白靶向探针的诊断和监测
EP3868774A1 (en) Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same
Mata et al. Tumor imaging using technetium-99m bound to pH-sensitive peptides
US20220118116A1 (en) Adhesive/adsorption switch on nanoparticles to increase tumor uptake and delay tumor clearance
Kaňa Targeted Polymer Macromolecules in the Treatment of Head and Neck Squamous Cell Carcinomas

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200812

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220111

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240328

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20241125

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D